AU2003225670A1 - Interferon drug therapy for the treatment of viral diseases and liver fibrosis - Google Patents
Interferon drug therapy for the treatment of viral diseases and liver fibrosisInfo
- Publication number
- AU2003225670A1 AU2003225670A1 AU2003225670A AU2003225670A AU2003225670A1 AU 2003225670 A1 AU2003225670 A1 AU 2003225670A1 AU 2003225670 A AU2003225670 A AU 2003225670A AU 2003225670 A AU2003225670 A AU 2003225670A AU 2003225670 A1 AU2003225670 A1 AU 2003225670A1
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- drug therapy
- liver fibrosis
- viral diseases
- interferon drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/006687 WO2004078194A1 (en) | 2003-02-28 | 2003-02-28 | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003225670A1 true AU2003225670A1 (en) | 2004-09-28 |
Family
ID=32961111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003225670A Abandoned AU2003225670A1 (en) | 2003-02-28 | 2003-02-28 | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| AU2003287145A Abandoned AU2003287145A1 (en) | 2003-02-28 | 2003-10-14 | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003287145A Abandoned AU2003287145A1 (en) | 2003-02-28 | 2003-10-14 | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2006522008A (en) |
| CN (1) | CN1764475A (en) |
| AU (2) | AU2003225670A1 (en) |
| CA (1) | CA2516776A1 (en) |
| WO (2) | WO2004078194A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034764B2 (en) * | 2003-10-21 | 2011-10-11 | Medtronic Minimed, Inc. | Modulation of SOCS expression in therapeutic regimens |
| JP2008519840A (en) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | How to treat diabetes |
| ES2546181T3 (en) | 2006-05-09 | 2015-09-21 | Genzyme Corporation | Methods of treating fatty liver disease by inhibiting the synthesis of glycosphingolipids |
| WO2008150486A2 (en) | 2007-05-31 | 2008-12-11 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| MX2007009796A (en) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
| BRPI0823522A2 (en) | 2007-10-05 | 2014-01-07 | Genzyme Corp | USE OF CERAMIDE DERIVATIVE COMPOUND |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| RU2398582C1 (en) * | 2009-01-19 | 2010-09-10 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Method of treating moderately active and replicative chronic viral hepatitis type c of 1-genotype |
| MX2011007675A (en) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans. |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SG2014011647A (en) | 2011-10-21 | 2014-08-28 | Abbvie Inc | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| MX346763B (en) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE. |
| MX356551B (en) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne. |
| JP7129703B2 (en) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806347A (en) * | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5980884A (en) * | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
-
2003
- 2003-02-28 AU AU2003225670A patent/AU2003225670A1/en not_active Abandoned
- 2003-02-28 WO PCT/US2003/006687 patent/WO2004078194A1/en not_active Ceased
- 2003-10-14 AU AU2003287145A patent/AU2003287145A1/en not_active Abandoned
- 2003-10-14 WO PCT/US2003/032539 patent/WO2004078193A1/en not_active Ceased
- 2003-12-23 CN CNA2003801102411A patent/CN1764475A/en active Pending
- 2003-12-23 JP JP2004569227A patent/JP2006522008A/en active Pending
- 2003-12-23 CA CA002516776A patent/CA2516776A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2516776A1 (en) | 2004-09-16 |
| WO2004078193A1 (en) | 2004-09-16 |
| AU2003287145A1 (en) | 2004-09-28 |
| CN1764475A (en) | 2006-04-26 |
| WO2004078194A1 (en) | 2004-09-16 |
| JP2006522008A (en) | 2006-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003225670A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
| IL165860A0 (en) | Administration of therapeutic viruses | |
| AU2003220317A1 (en) | Methods and drug delivery systems for the treatment of orofacial diseases | |
| IL157364A0 (en) | Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1 | |
| IL169338A0 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
| AU2003225281A1 (en) | Materials and methods for prevention and treatment of rna viral diseases | |
| AU2002329990A1 (en) | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | |
| AU2003261251A1 (en) | Methods of delivering therapeutic agents | |
| AU2002322719A1 (en) | Delivery of therapeutic capable agents | |
| WO2003072035A8 (en) | Compositions and methods for the treatment of immune related diseases | |
| PL377854A1 (en) | Nasal pharmaceutical formulations and methods of using the same | |
| AU2003259381A1 (en) | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases | |
| AU2003261237A1 (en) | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | |
| WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU3009801A (en) | Combinations of medicaments for treating viral diseases | |
| AU5618501A (en) | Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis | |
| ZA200707934B (en) | Thereapeutic formulations for the treatment of beta-amyloid related diseases | |
| AU2003299962A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
| AU2003273983A1 (en) | Viral vectors and the use of the same for gene therapy | |
| AU2002359618A1 (en) | Medicinal compositions and therapeutic methods | |
| AU2002325169A1 (en) | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | |
| AU2003256280A1 (en) | Methods of delivering gene therapy agents | |
| AU2003270540A1 (en) | Treatment of cyclooxygenase-3 mediated diseases and disorders | |
| AU5611701A (en) | Agent for the diagnosis and therapy of viral diseases | |
| AU2003240052A1 (en) | Il-11 derivatives and therapeutic uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |